What is the optimal serum lithium level in the long-term treatment of bipolar disorder -: a review?

被引:96
作者
Severus, W. E. [1 ]
Kleindienst, N. [2 ]
Seemueller, F. [1 ]
Frangou, S. [3 ]
Moeller, H. J. [1 ]
Greil, W. [1 ,4 ]
机构
[1] Univ Munich, Dept Psychiat, D-80336 Munich, Germany
[2] Cent Inst Mental Hlth, Mannheim, Germany
[3] Inst Psychiat, London, England
[4] Sanatorium Kilchberg, Kilchberg, Switzerland
关键词
bipolar disorder; lithium; long-term treatment; prevention and control; recurrence; review;
D O I
10.1111/j.1399-5618.2007.00475.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: There is substantial uncertainty about the most efficacious serum lithium level for the long-term treatment of bipolar disorder (BD). This review focuses on the available evidence taking into consideration the effects of previous lithium history, changes in lithium level and polarity of relapse or recurrence. Methods: We conducted a MEDLINE search, using the MeSH Terms 'bipolar disorder' and 'lithium' together with 'randomized controlled trial' or 'controlled clinical trial' covering the time span from 1966 to March 2006. We only included studies reporting on the long-term treatment of mood disorders where patients with BD were examined as a separate group and were assigned to precisely specified target ranges of lithium level. Results: The minimum efficacious serum lithium level in the long-term treatment of bipolar disorder was 0.4 mmol/L with optimal response achieved at serum levels between 0.6 - 0.75 mmol/L. Lithium levels > 0.75 mmol/L may not confer additional protection against overall morbidity but may further improve control of inter-episode manic symptoms. Abrupt reduction of serum levels of more than 0.2 mmol/L was associated with increased risk of relapse. Conclusions: In the long-term treatment of bipolar disorder clinicians should initially aim for serum lithium levels of 0.6 - 0.75 mmol/L, while higher levels may benefit patients with predominantly manic symptoms.
引用
收藏
页码:231 / 237
页数:7
相关论文
共 28 条
  • [1] AHMED S, 2004, NEURORX, V1, P507
  • [2] Baldessarini RJ, 1997, AM J PSYCHIAT, V154, P551
  • [3] A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder
    Bowden, CL
    Calabrese, JR
    McElroy, SL
    Gyulai, L
    Wassef, A
    Petty, F
    Pope, HG
    Chou, JCY
    Keck, PE
    Rhodes, LJ
    Swann, AC
    Hirschfeld, RMA
    Wozniak, PJ
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (05) : 481 - 489
  • [4] A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder
    Bowden, CL
    Calabrese, JR
    Sachs, G
    Yatham, LN
    Asghar, SA
    Hompland, M
    Montgomery, P
    Earl, N
    Smoot, TM
    DeVeaugh-Geiss, J
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (04) : 392 - 400
  • [5] A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder
    Calabrese, JR
    Bowden, CL
    Sachs, G
    Yatham, LN
    Behnke, K
    Mehtonen, OP
    Montgomery, P
    Ascher, J
    Paska, W
    Earl, N
    DeVeaugh-Geiss, J
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (09) : 1013 - 1024
  • [6] DECREASING LITHIUM DOSAGE REDUCES MORBIDITY AND SIDE-EFFECTS DURING PROPHYLAXIS
    COPPEN, A
    ABOUSALEH, M
    MILLN, P
    BAILEY, J
    WOOD, K
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1983, 5 (04) : 353 - 362
  • [7] COMPARISON OF STANDARD AND LOW SERUM LEVELS OF LITHIUM FOR MAINTENANCE TREATMENT OF BIPOLAR DISORDER
    GELENBERG, AJ
    KANE, JM
    KELLER, MB
    LAVORI, P
    ROSENBAUM, JF
    COLE, K
    LAVELLE, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1489 - 1493
  • [8] Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology
    Goodwin, GM
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (02) : 149 - 173
  • [9] Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - A randomised study
    Greil, W
    LudwigMayerhofer, W
    Erazo, N
    Schochlin, C
    Schmidt, S
    Engel, RR
    Czernik, A
    Giedke, H
    MullerOerlinghausen, B
    Osteheider, M
    Rudolf, GAE
    Sauer, H
    Tegeler, J
    Wetterling, T
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1997, 43 (02) : 151 - 161
  • [10] The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III:: Maintenance treatment
    Grunze, H
    Kasper, S
    Goodwin, G
    Bowden, C
    Möller, HJ
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2004, 5 (03) : 120 - 135